Singapore’s Health System Holds Promise To Develop Drug Monitoring Devices
This article was originally published in PharmAsia News
With Singapore’s biomedical infrastructure and small population, it is an ideal place to test devices that could redefine the way therapies are developed and monitored.
You may also be interested in...
Some ideas for new drug approval pathways seem to envision the use of Risk Evaluation and Mitigation Strategies as a means for preventing and monitoring off-label use following initial approval, apparently without regard to the seriousness or extent of a product’s risks. Given the burdens currently created by REMS, any effort to expand and retrofit the programs to a new approval pathway is likely to draw pushback from the health care community.
U.S. FDA could help create several international coalitions to carry out its new globalization plan, which could allow for issue-specific groups focused on individual pharmaceutical sectors
SHANGHAI - Both challenges and opportunities exist for conducting post-marketing safety studies for drugs, but the opportunities far outweigh the challenges, Bristol-Myers Squibb VP Medical Safety Amrit Ray said Oct. 30 at Shanghai Institute for Food and Drug Safety's 2008 Drug Safety and Public Policy International Conference